Clinical trial NCT06087276: Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
Official title: Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Withdrawal, and Long-term Safety Study to Evaluate the Efficacy and Safety of Ulixacaltamide (PRAX-944) in Adults With Essential Tremor
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Essential Tremor
Keywords: Movement Disorder
Benign Essential Tremor
Familial Tremor
Hereditary Essential Tremor
Movement Disorder Agents
Calcium Channels, T-type
Lead sponsor: Praxis Precision Medicines
Sponsor class: INDUSTRY
First posted: 2023-10-17
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: * Parallel Design: A 12-week parallel design (PD) randomized, double-blind, placebo-controlled study to evaluate the proportion of participants that respond to and the efficacy and safety of ulixacaltamide compared with placebo.
* Randomized Withdrawal: A 12-week randomized withdrawal (RW), double-blind, placebo-controlled study to evaluate the efficacy, maintenance of response, and durability of effect in participants who respond to ulixacaltamide and safety.
* Long-term Safety Study: A LTSS study to evaluate the long-term safety of ulixacaltamide for up to 1 approximately 1 year. The first 2 weeks of the LTSS will be double-blind.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor. The main question it aims to answer is:

• Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor?

Participants will be asked to participate in one of two clinical studies where they will be treated with either ulixacaltamide or placebo for a period of up to 12 weeks. After the controlled study completion, they will be eligible to participate in a long-term, open-label safety study and be treated with ulixacaltamide.

Detailed description: PRAX-944-321 is a decentralized, Phase 3, multi-study, clinical trial evaluating the safety and efficacy of ulixacaltamide in essential tremor (ET). The study includes 2 separate and simultaneous phase 3 pivotal studies, of which one is a parallel design (PD) and the other a randomized withdrawal (RW), with all participants undergoing one screening process and a long-term safety study (LTSS). This study also includes a separate LTSS study for eligible pivotal study and PRAX-944-222 open label extension (OLE) participants.

Eligibility criteria: Inclusion Criteria:

1. Has a body mass index (BMI) at Screening of ≥18 kg/m2.
2. Has a clinical diagnosis of ET confirmed during screening and characterized by postural and action tremor.
3. If currently receiving medication prescribed for ET, must be on ≤1 medications, on stable dose(s) for at least 1 month prior to Screening, and willing to maintain stable dose(s) throughout the study. As needed (PRN) use of prescribed ET medicines is not allowed with the exception of propranolol PRN. Participants prescribed propranolol PRN are eligible but must discontinue the PRN dose after the first day of screening. Primidone use is not allowed within 2 weeks prior to screening and throughout duration of study.
4. Women of childbearing potential must undertake pregnancy tests, with a documented negative serum pregnancy test at Screening, negative urine pregnancy tests at Baseline (Day 1) prior to administration of study drug, throughout the intervention periods (as outlined in the SoA) and at the SFU or ED Visit, as appropriate.
5. Is willing and able to use contraception as defined in the protocol and ICF.
6. Has been assessed as an appropriate and suitable candidate by investigator and has a neurological exam and medical record(s) consistent with ET diagnosis, as confirmed by the ERC central reviewer.
7. Confirm key inclusion criteria at Baseline

Exclusion Criteria:

1. Neuropathy, muscle weakness, arthropathy or other musculoskeletal diagnosis of the upper extremity that impairs dexterity or function.
2. Has a known hypersensitivity to any component of the formulation of ulixacaltamide.
3. Is unwilling or unable to refrain from episodic use of medication(s)/substance(s) that might interfere with the evaluation of tremor during the study.
4. Is sporadically using a benzodiazepine, sleep medication or anxiolytic (as further defined in the protocol), that in the judgement of the investigator or sponsor would confound the assessment of tremor.
5. Has trauma to the nervous system within 3 months preceding the onset of tremor.
6. Has a history of unilateral tremor or clinical evidence of another medical, neurological, or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, Huntington's disease, Alzheimer's disease, stroke with neurologic sequelae, intention tremor (IT) caused by etiology other than ET, cerebellar disease (including spinocerebellar ataxias), primary dystonia, Fragile X Tremor/Ataxia syndrome or family history of Fragile X syndrome, traumatic brain injury, psychogenic tremor, alcohol or benzodiazepine abuse or withdrawal, multiple sclerosis, polyneuropathy (diabetic neuropathy allowed if disease does not affect gait or balance and does not involve upper extremity), and endocrine states such as uncontrolled or inadequately treated hypothyroidism, food, or supplement induced movement disorders (e.g., tremor related to beta agonists or caffeine), or other medical, neurological, or psychiatric conditions that may explain or cause tremor.
7. Has had prior magnetic resonance-guided focused ultrasound or surgical intervention for ET such as a deep brain stimulator (DBS) or lesion therapy such as thalamotomy.
8. Has had botulinum toxin injection for ET in the 6 months prior to Screening or throughout the study.
9. Is using the Cala trio health device for ET in 14 days prior to Screening or throughout the study.
10. Is unwilling or unable to refrain from drinking alcohol 24 hours before and during clinical study assessments, or regular use of alcohol that would preclude abstinence from alcohol for this time period around visits.
11. Has a history of substance use disorder consistent with Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision (DSM-5-TR) criteria. Participants with a previous diagnosis of substance use disorder who have been in remission for at least 2 years can participate in the study.
12. Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 31 days of the last study drug dose.
13. Is currently taking a prescription or non-prescription product(s) and food known to be moderate or strong inhibitors or strong inducers (moderate inducers are not prohibited) of cytochrome P450 (CYP3A4), which cannot be discontinued at least 5 half-lives or 14 days prior (whichever is the longer period of time) to Baseline and withheld throughout the clinical study.
14. Has received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening.
15. Has any of the following abnormal test results at Screening: a serum total bilirubin value \>1.5×upper limit of normal (ULN); a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \>2×ULN. As an exception, participants that present with elevated bilirubin in the absence of elevations in ALT or AST that fits the pattern of Gilbert's syndrome may be enrolled after discussion with the medical monitor and/or sponsor designee if their conjugated bilirubin is below the ULN.
16. History of human immunodeficiency virus (HIV) infection or positive screening result for: HIV 1 or 2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCVAb).
17. History of long QT syndrome and/or a Fridericia formula corrected QT interval (QTcF) interval \>450 msec (males) or \>460 msec (females) per electrocardiogram (ECG) done at Screening.
18. Any major psychiatric disorder, including but not limited to depression and anxiety, that is uncontrolled (for the past 90 days) or, in the investigator's judgment, can interfere with any of the study procedures.
19. Has a lifetime history of any suicide attempt, or suicidal ideation with intent within the past 2 years prior to Screening.
20. Participants who have a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years prior to screen are excluded.

    Exceptions:
    * Participants with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ are permitted at any time.
    * Participants with a history of other malignancies deemed cured by adequate treatment are also permitted at any time.
21. Has any other significant disease or disorder including but not limited to uncontrolled seizure or epilepsy, diabetes, cardiovascular disease, renal disease, laboratory abnormalities, or environmental factor that, in the opinion of the investigator or sponsor designee, may either put the participant at risk due to participation in the clinical trial, may influence or confound the result of the clinical trial, or may affect the participant's ability to participate in the clinical trial. Uncontrolled epilepsy or seizure is exclusionary and is defined as a seizure or epilepsy diagnosed by a medical clinician and a documented seizure or change in seizure medication (medication or dose) in the last 2 years. An estimated glomerular filtration rate (eGFR) of \<60 using the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) formula mL/min/1.73m2 or urine albumin creatinine ratio (uACR) of ≥ 30 mg/g is exclusionary.
22. Participant has a positive alcohol or drug screening (including cannabis and cannabis-derived products). The participant can be enrolled in the study, if they are willing to stop use of cannabis or cannabis-related products after the Screening Visit and have a negative cannabidiol (CBD) screen result at Baseline (Day 1). A positive amphetamine, benzodiazepine or opioid drug screening result could be allowed if it is determined that the result is a false positive (for example caused by another medication), or if the result is due to a documented prescribed medication (for example: benzodiazepine or opioid) that in the opinion of the investigator or sponsor designee, is prescribed for a medical condition that aligns with standard of care, is not associated with substance abuse and the investigator's assessment determines that the medical condition and medication dose is stable and expected to remain stable throughout the trial.
23. History of or evidence of psychogenic tremor
24. Prior participation in an ulixacaltamide clinical trial at any time or other clinical trial evaluating a potential drug for ET in the past 6 months (with the exception of participants with documentation that they received placebo treatment only), with the exception of participants that are currently enrolled in and complete the EOT visit in PRAX-944-222 extension period.

Primary outcomes:
measure: Parallel Design: Change from Baseline (CFB) to Week 12 (Day 84) on mADL11
timeFrame: 12 weeks (84 days)
measure: Randomized Withdrawal: The proportion of participants that maintain response, as defined by change in mADL11 score, following randomized withdrawal
timeFrame: 12 weeks (84 days)
measure: Long-term Safety Study: Number of participants with Adverse Events (AE) and their severity.
timeFrame: Up to 52 weeks (365 days)
Secondary outcomes:
measure: Parallel Design: The proportion of participants responding to ulixacaltamide, as defined by change in mADL11 score after 12 weeks (84 days) of treatment
timeFrame: 12 weeks (84 days)
measure: Parallel Design: TETRAS-ADL Change from Baseline to Week 12 (Day 84)
timeFrame: 12 weeks (84 Days)
measure: Parallel Design: PGI-C Change from Baseline to Week 12 (Day 84)
timeFrame: 12 weeks (84 Days)
measure: Parallel Design: CGI-S Change from Baseline to Week 12 (Day 84)
timeFrame: 12 weeks (84 Days)
measure: Parallel Design: PGI-S Change from Baseline to Week 12 (Day 84)
timeFrame: 12 weeks (84 Days)
measure: Parallel Design: Proportion of participants responding to ulixacaltamide, as defined by change in mADL11 score after 14, 28, 56, and 70 days of treatment
timeFrame: 10 weeks (70 days)
measure: Parallel Design: mADL11 Change from Baseline to Day 14, Day 28, Day 56, and Day 70
timeFrame: 10 weeks (70 days)
measure: Parallel Design: TETRAS-ADL Change from Baseline to Day 14, Day 28, Day 56, and Day 70
timeFrame: 10 weeks (70 days)
measure: Parallel Design: PGI-C Change from Baseline, Day 28, Day 56, and Day 70
timeFrame: 10 weeks (70 days)
measure: Parallel Design: CGI-S Change from Baseline to Day 14, Day 28, Day 56, and Day 70
timeFrame: 10 weeks (70 days)
measure: Parallel Design: PGI-S Change from Baseline to Day 14, Day 28, Day 56, and Day 70
timeFrame: 10 weeks (70 days)
measure: Parallel Design and Randomized Withdrawal: Dominant Hand Archimedes Spiral (Day 1, Day 56, Day 84)
timeFrame: 12 weeks (84 days)
measure: Randomized Withdrawal: mADL11 Change from RW Baseline (Day 56) to Day 63, Day 70, Day 77, and Day 84
timeFrame: 4 weeks (28 days)
measure: Randomized Withdrawal: TETRAS-ADL Change from RW Baseline (Day 56) to Day 63, Day 70, Day 77, and Day 84
timeFrame: 4 weeks (28 days)
measure: Randomized Withdrawal: PGI-C Change from RW Baseline (Day 56) to Day 63, Day 70, Day 77, and Day 84
timeFrame: 4 weeks (28 days)
measure: Randomized Withdrawal: CGI-S Change from RW Baseline (Day 56) to Day 63, Day 70, Day 77, and Day 84
timeFrame: 4 weeks (28 days)
measure: Randomized Withdrawal: PGI-S Change from RW Baseline (Day 56) to Day 63, Day 70, Day 77, and Day 84
timeFrame: 4 weeks (28 days)
measure: Parallel Design and Randomized Withdrawal: Number of participants with Adverse Events (AE)
timeFrame: 12 weeks (84 days)
Other outcomes:
Locations:
city: Morgantown
country: United States
facility: United BioSource LLC
state: West Virginia
Study officials:
affiliation: Praxis Precision Medicines
name: Director, Clinical Development
role: STUDY_DIRECTOR
References: